President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

The restricted mean survival time (RMST) analysis technique was introduced in health care research about 25 years ago and since then has become widely used in economics, engineering, business and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses.

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to ...

Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while larger, federally licensed compounders have until May 22 to keep producing ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...